Thanks Laura. afternoon, call Good today. everyone. joining the Thanks, for
the announced we've recently, During achievement earlier made today, key towards goals. our the significant we progress fourth of quarter and some more as
recent position ischemic is stroke, evaluating initiation Japan, Japan in trial call, Healios last MultiStem evaluating partnerships clinical and and will to study of MultiStem our financial the a America the conduct which media been the evaluate awareness critical the solid Europe, ischemic of to pivotal new need. for TREASURE These financial activities the preparing to investor our of strengthening of in through a balance strengthen achieving company Phase cells in clinical relations, said overarching to X successfully substantial earnings and supporting capabilities. relations therapy we establish as are the position, developing have Athersys with in corporate stroke advance goal and our patients areas establishing building As innovative our in to the address suffered and maintaining biopharma administration administration portfolio therapies our priorities communications collaborations potential and patients and have unmet of an MASTERS-X our leading and programs, of that trial, by expanding the North our sheet that to objectives
focus As have intent were we heavily I recent mentioned on collaboration expand our potential earnings evaluating significantly to a has letter today, on we of and collaborative Healios. binding in call commercialization been November, development and our announce the with last that entered into Earlier concentrated activities. pleased partnering existing to
TREASURE design time, investment Japan at study. the connection In XX collaboration MultiStem began initial treatment equity Our yesterday's Healios the expansion, develop to registrational that trial closing Healios a $X.XX via closely we our of with on envisioned XX% worked per share and in with ongoing the Japan. common price. of launch million million Healios XXXX price is stock, as of a And have of license in for ischemic of their and the stroke a purchase in shares a reflecting with referred premium the to $XX.X to making since
on basis Japan, license license license escrow addition, additional over indications represents next for rights. in related obtain bud that In a a a MultiStem disease global weeks. of are to for the April develop to their other the trauma and to work expansion million respiratory by to to treatment actively account acute us, for as of into collaboration in and agreement terms deposit among and the and a that use or including fee the intend MultiStem an ARDS ophthalmological an would the finalize $XX working XX, indications of we MultiStem well broad expanded guaranteed we develop while organ several distress specific collaboration will certain Under Healios agreements as the exclusive expansion on complete Healios payment syndrome for to organ technology
and are combination is exclusive the payments, option April a by the in develop required the occur option to million guaranteed agreement into the XX, pay a option of payments its In over China becomes or exchange initial stroke, the license and Healios payment million which to each in in by also terminated license payments on abrogated trauma be basis. trial, not China. we million Athersys payments although Healios of If $XX for payments $XX royalties against a These broader and license funding from the Once could license China. and rights, ARDS for agreement Healios would the in obligation licenses China, May to under escrow in and enter required paid would time. million and option the profit for indication XXXX credit account, the fees. $XX exercise additional as due broader quarterly from in or expansion treatment milestone trauma And quarterly MultiStem including the payment for obtain any to would execution Healios these installments Ischemic milestone a Athersys by for a used be TREASURE collaboration the X, reflecting is and nonrefundable, option broader in in Importantly, include for collaboration elects payment the documents, license payments of effective license may which fees, certain the license ARDS for receive an share be and following or associated otherwise MultiStem of result stroke, expansion or and commercialize thereof upon collaboration expansion an fees, collaboration the $XX the escalating Japan.
such moment ARDS, the if the for escrow. a for and be of conjunction execution of or the addition fund license of XX, certain associated is buds collaboration the investment, a with to required As organ with LOI to payments expanding on of $XX for MultiStem the executed moment indications to agreement XXXX, the the in of the agreement either is described as in the include ophthalmological LOI, will under the released payment scope in expansion organ as That and before equity portion diseases. portion of I not execution the into to Healios April broad ago Athersys use Japan binding the or current $XX amount million million initial noted ago,
narrower escalates the to initial the effective In is Healios in addition warrant its Healios for Athersys’ right, but million recently is clear may the the of floor established license respect sufficient conduct a not expertise to with will to and importantly, Furthermore, is rapid, this this obligation key of purchase and purchase cap Japan expand they certain but the just acquire XXXX effective greater in stock. transaction see that that be additional stock Healios opportunities on conditions limitations, fixed as price our to expansion potential also us a competitive trial. our price to meaningful access with accelerate and warrant X, XX.X% MultiStem it collaboration other September commitment, multiple execute and It shares conditions term warrant of Athersys will time efficient develop to From signal indications A becomes over it and our exercise as on shares and based that that puts regenerative in if warrant The global a I under price Perhaps in other receive transaction the of including if the is mutual of price. to shares ability important shares ARDS respect provides have XXXX in exercisable to subject the is stock strong common an cost to becomes of agreement. current fail framework. total development where provides exercised also a position common market capital programs investment, shares a to with XX alignment. in that of the other give license minimum of then will of there respect a and of MASTERS-X warrant implemented the during position. under the medicine the only until Healios equity for a manner floating number goal development a including a common the strong perspective, initiatives, certain April, with not Athersys’ the Japan of we implemented and broader and outstanding and through the mentioned collaboration TREASURE us to
as Healios be for had collaboration years, election in as equity our accomplishments. of record election with subject Having XXXX. Hardy pleased into to of agreement if and to is the especially the CEO April, joining visionary highly shareholders, board Athersys nominated stockholders' would the Hardy Board he leader effective expansion will outstanding CEO Directors We scheduled directors to Dr. in of Healios of opportunity I work our with the to several a meeting by pleased are Kagimoto, of regard be part to at past next a the announce that of that entered investment, I'm be an over track him annual June
mentioned, move now in organizationally. additional level this move I summary, through and our alignment capital million meaningful resources Healios. in Athersys throughout provide XX.X of our us a is which substantial will with collaboration to visions expansion I strongly position. with information with are over As additional Healios commitment guaranteed weeks at organizational broader as provide strong collaboration earlier our of and enables announcement aligned, expansion Athersys the the to both with believe forward investments regards payments In the of and shareholder the leadership potential Healios a and perspective, financial Athersys stronger to enactment $XX.X for of today, million to even the meaningful and We’ll and between with these shareholders the equity companies. coming activities From forward we an complete establishes the it time confidence with
in the and collaboration, Healios clinical regarding TREASURE progress has further the additional been enrollment addition In the with with progress an our of expansion patients there our of of to sites. trial addition
a we as as commitment to there soon conveyed and of possible. completing previously, Healios enrollment the the As have is strong trial
as issues patient analyzed, months TREASURE we subsequently the and top the our shareholders of Lonza, February available Healios line placebo. to after the the and with sometime of approval data the timetable complete experienced the call, would will several results of manufacturer collected, for After suspension and the basis the be provide impact year for for enrolled earnings trial XXXX the due know, reflect the of fall the during enrolment and to assessed to trial the last their be a our manufacturing trial be the completion As already then adjusted intend temporary been some in the visit. PMDA. incorrect to last formulation last they at of contract To the the clear, has of their anticipate, verified are organized, line and hope will top results data submission we If XX-day is announced. line they top Healios
a a be the year and will of Some a of have approval. of for full our or shareholders results in evaluation been the confused the the patients for fact the that announcement by trial timing that what might on one potential impact year of have bit submission evaluated
data So to MultiStem a in double will the time, blind following or year patients evaluated MASTERS-X XX-day conditional basis they in during assessment submission as placebo received successful. whether These their the a nor endpoint either will patients was a is physicians primary manner for provide to neither be of the the study. or know full or clinical PMDA for and results if will while primary case will provide the that trial clarify, previously, for the enrolment the the approval basis the trial full for
until year the will evaluation approximately study the process that enrollment has the year continue expected projected of last is patient the the this trial one one While Healios and for in latter to earlier beyond will for analysis three part of data. and more primary final XXXX, collection, results the month the eight approximately verification several be visit the months available weeks from the then of TREASURE following trial and the continue
remained we challenges, keys is and in of That was and that result productive serves to the experienced to partnership. Throughout important issues also it our year, and of mutual a the to While Healios underscore are and decision needed necessary to strong as as obstacles led these a last this we one point. adjustment fully an address we the issues to aligned. coordinated and we’ve manner expand alignment work
also team with as of need Healios another area other is which to in engage PMDA in additional indications ARDS, common clinical of with few past Over unmet regarding the such the interest, considerable weeks, worked we've interactions Japan.
such As and well our the in results in believe gained of US we positioned the the that we're is from for ARDS will study already with the we Healios engaged effectively the subsequent to process. experts approached of the Healios and and that and engaging completion clinical knowledge conducted PMDA a Japan. that trial we trial preparing trial assisting them in in apply are has UK, actively ongoing by here be key a ongoing
Another is area interest in trauma. of common
the could Over MultiStem multiple with from trauma, the working years, that several past few groups, published reflecting be a in independent range studies leading we area. beneficial in research specifically models, how of neurological illustrate damage have
or Some individuals the the and members the The is or the and of for US it can million that three X disability XXX,XXX to traumatic hospitalizations. are related year for the the disability living most a -- third noticed more in reports are that each bleeding the being million inflammation response shock associated with people treatment well complications Among Disease of TBI three disability remaining US estimated more and and its XXXX, military. but cost swelling acute damage inflammatory tissue Of each especially that as and with visits XX% XXX,XXX TBI. CDC rate indicate $XX.X the serious injury injury the result collaborators thromboembolic suffer of respiratory company in among in young TBI that due failure, include to XX% systemic and complications, evaluated, department others of billion Centers X.X trauma. at the which death US kidney neurological secondary the recent infections. people our injury, over poor disease, leading inflammatory people After well from follow XX,XXX clotting of from TBI accounts it’s than and more relevance the in occur people injury, TBI in deaths blood or of X organ cause an in of syndrome trauma CDC, serious serious estimated initial Control for there of syndrome, suffer living in XX,XXX year million acute closely resuscitation. than deaths brain an disability, fatalities as of significant related as death -- and emergency that cause According multiple ARDS, year. immune for the US to trauma is related days, were broadly this after in trauma distress approximately and as the venous a first cause a are the vessel or after age the leading death annually. at a of and low, uncontrolled steady and cause under primarily leading of These potential occur XX days
end the cell injury. of X US plans one with soon evaluating severe with agencies and with therapy that announce the prevention provided initial funding after the the one the traumatic injury, including that Our it has both well treatment damage blood of collaborates the following as the as and of occurs complications for and we multiple and preclinical to the of injury MultiStem various believe working Athersys’ in new and in reduction cells, types complications the Phase of participating considerable We protection leading for data traumatic promote will independent consistently healing tissue cascade early such kidneys. center. and to the centers field experts inflammatory from inflammation mitigates Accordingly, to following causes clinical other the of as trauma in indicates recruitment that the level of ways, and organs to leading vessels of administration MultiStem cell potential repair and MultiStem stimulation respond and trial, conduct trauma support damage signals of injured consortium government lungs tissue the
work another earlier, support to our in development area included institutions This various expansion and part ability collaborators I be to work initiatives. collaboration as indications partners of as successfully of clinical followed our focused that to and funding is with trauma the serves pre-clinical the and would illustration described secure the As one with closely. Healios of as has who
another earlier, a as we've that been to Laura from a done some received This objective mentioned of minutes shareholders our we've me described sheet questions weeks. of ago, few maintain leads has in As some just to and that. the key recent solid balance
it financing we to vehicle or names obligation we've to last want effect, Aspire form choose many intent In each the backstop whenever questions could sell questions to additional the to, We use of received not The an the policy. I'm to if is that question, associated asked around, provides a sheet. and representative we answers. I so we vehicle from healthy it feel we're that we significance insurance whenever a can but shareholders the no balance in this shares recently need that of have call, Several yet. with under and people significance form maintain present is the going of facility whether to. the we Aspire time the Although of and have about corresponding a simply announced utilize Aspire vehicle used the
Over of the avoid balance maintain dilutive facility financing. an sheet we've quarters, stable prior to and past the a used the excessively doing several risk
$X shareholders appreciate appreciate thanked no. us have which is the Some the $X answer shareholders Aspire Other yet. have made of the upfront and new proactive asked investment, the we whether Other used per share, Aspire’s million that. steps that we interest protect have to than was their importance of taking our and recognize and at own our for and vehicle
used not it. have We
an to whether we Board we conduct Other or the feel no Our a the use plans asked banker given vehicle. no. financing. engage always or is to have investment but planning the no circumstances, intention option are retains is do to whatever immediate answer even appropriate, have rights shareholders financing or we an whether The we the currently institutional immediate such
immediate do We as such have always, it whatever board reserves to the our shareholders. term serve prudent conduct the appropriate financing, interest a feels is to to the right and of no plans but
comments, regards progress and to TREASURE the multiple as additional recent enrolled the any both I my to we the yes, in are been with enrolled they this whether reaffirm, patients. shareholder trial with there's just Japan asked patients have earlier Another addressed in progress in trial. pleased Healios but
Another initiate quarter the to study shareholder we are intend asked track about and MASTERS-X when the We're so. second on the doing trial? initiate to in excited
The to and the can in of final in Another about off short that China that is expectation of recent Athersys potential partnering and but accepting conservative My we This developments based yes. we Healios or question explore in answer trial it in one we but get we is today coming good possibility. earlier that and is TREASURE results answer evaluation clinical the will trials have likely posed is has shareholder opportunities. a whether is something would the have A MultiStem that approval in regards China to yet, engaged could that regards a conduct is outside more China, it be that the been together. question whether to for still trial are asked out of results. don't
a of we have might few evaluate partnership. the new shareholders, about been to such major continue We opportunities. are quite a some received we submitted although announce by when our questions Those that
time effectively -- may one we we think being. I have for addressed that the
that, with open questions like So few I'd in. a up to it from calling for people
